Characterizing CLDN18.2 and HER2 expression in gastroesophageal cancerTempus RWD reveals CLDN18.2 and HER2 are independent biomarkers in GE cancerINDICATIONGastricBIOMARKERCLDN18.2Related casesComparing molecular landscapes of early and average onset enteropancreatic NETsOutcomes analysis in HER2-low gastric cancer using multimodal RWDDeveloping a gene expression signature for first-line treatment in metastatic CRC
